PM

Prosight Management Portfolio holdings

AUM $580M Turnover 39.22%
1-Year Est. Return 29.81%
This Fund
S&P 500
This Quarter Est. Return
+1.17%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$406M
AUM Growth
+$71.8M
Cap. Flow
+$62M
Cap. Flow %
15.25%
Top 10 Hldgs %
55.4%
Holding
62
New
16
Increased
17
Reduced
12
Closed
17
Avg Time Held Equity + Options
0.7 years
Top 10 Avg Time Held Equity + Options
0.7 years
Top 20 Avg Time Held Equity + Options
0.8 years
Avg Time Held Equity only
0.8 years
Top 10 Avg Time Held Equity only
0.7 years
Top 20 Avg Time Held Equity only
0.8 years

Top Buys

Rank Stock Value
1
MCK icon
McKesson
MCK
+$19.9M
2
ABCL icon
AbCellera Biologics
ABCL
+$18.6M
3
DXCM icon
DexCom
DXCM
+$9.09M
4
JANX icon
Janux Therapeutics
JANX
+$8.92M
5
BBIO icon
BridgeBio Pharma
BBIO
+$7.53M

Top Sells

Rank Stock Value
1
KELYA icon
Kelly Services Class A
KELYA
+$10.5M
2
LKFT icon
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$8.74M
3
ALKS icon
Alkermes
ALKS
+$6.63M
4
KIDS icon
OrthoPediatrics
KIDS
+$5.76M
5
OPCH icon
Option Care Health
OPCH
+$5.68M

Sector Composition

Rank Sector Weight
1 Healthcare 94.39%
2 Miscellaneous 2.95%
3 Industrials 2.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
COGT icon
26
Cogent Biosciences
COGT
$4.88B
$4.44M 1.09%
410,830
-89,170
-18% -$868K
2024 Q1
2 quarters
FLNA icon
27
PUT
Filana Therapeutics
FLNA
$35.3M
$4.38M 1.08%
+148,900
New +$3.43M
2024 Q3
0 quarters
BPMC icon
28
DELISTED
Blueprint Medicines
BPMC
$4.36M 1.07%
+47,100
New +$4.68M
2024 Q3
0 quarters
TECX icon
29
Tectonic Therapeutic
TECX
$410M
$4.17M 1.03%
137,614
+70,153
+104% +$1.28M
2024 Q1
2 quarters
CTMX icon
30
CytomX Therapeutics
CTMX
$486M
$3.57M 0.88%
+3,022,109
New +$3.84M
2024 Q3
0 quarters
SGHT icon
31
Sight Sciences
SGHT
$454M
$3.35M 0.82%
+531,222
New +$3.57M
2024 Q3
0 quarters
VKTX icon
32
Viking Therapeutics
VKTX
$3.24B
$3.04M 0.75%
48,000
-67,000
-58% -$3.93M
2024 Q1
2 quarters
RCKT icon
33
Rocket Pharmaceuticals
RCKT
$243M
$2.94M 0.72%
+159,369
New +$3.26M
2024 Q3
0 quarters
CRBP icon
34
Corbus Pharmaceuticals
CRBP
$85.3M
$2.68M 0.66%
+130,000
New +$6.65M
2024 Q3
0 quarters
MURA icon
35
DELISTED
Mural Oncology
MURA
$1.79M 0.44%
570,620
+95,162
+20% +$310K
2023 Q4
3 quarters
MRVI icon
36
Maravai LifeSciences
MRVI
$976M
$1.73M 0.43%
+208,200
New +$1.8M
2024 Q3
0 quarters
VINC icon
37
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$1.58M 0.39%
110,325
-14,096
-11% -$193K
2024 Q2
1 quarter
RNTX icon
38
Rein Therapeutics
RNTX
$50.6M
$1.32M 0.32%
372,157
+107,157
+40% +$286K
2024 Q2
1 quarter
CRVL icon
39
PUT
CorVel
CRVL
$4.06B
$915K 0.23%
+8,400
New +$840K
2024 Q3
0 quarters
SEM icon
40
DELISTED
Select Medical
SEM
$909K 0.22%
+48,377
New +$927K
2024 Q3
0 quarters
OVID icon
41
Ovid Therapeutics
OVID
$428M
$860K 0.21%
729,208
-345,792
-32% -$361K
2024 Q1
2 quarters
IMNM icon
42
Immunome
IMNM
$2.03B
$572K 0.14%
39,135
-25,865
-40% -$368K
2024 Q2
1 quarter
IMRX icon
43
Immuneering
IMRX
$221M
$473K 0.12%
190,000
-360,000
-65% -$524K
2024 Q2
1 quarter
ACHC icon
44
Acadia Healthcare
ACHC
$2.95B
$359K 0.09%
+5,666
New +$409K
2024 Q3
0 quarters
STTK icon
45
CALL
Shattuck Labs
STTK
$535M
$303K 0.07%
+86,800
New +$324K
2024 Q3
0 quarters
ADUS icon
46
Addus HomeCare
ADUS
$2.18B
– –
-12,500
Closed -$1.45M –
ALKS icon
47
Alkermes
ALKS
$6.56B
– –
-275,000
Closed -$6.63M –
BCRX icon
48
BioCryst Pharmaceuticals
BCRX
$2.06B
– –
-398,700
Closed -$2.46M –
BMEA icon
49
Biomea Fusion
BMEA
$60.5M
– –
-124,377
Closed -$560K –
CVS icon
50
CVS Health
CVS
$116B
– –
-40,000
Closed -$2.36M –
1
2
3

Similar funds

SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
CCWM
Correct Capital Wealth Management Clayton, Missouri $580M AUM 16.45% 1-Year Est. Return
CMA
Cedar Mountain Advisors Lake Oswego, Oregon $581M AUM 18.16% 1-Year Est. Return
RIS
Retirement Income Solutions Ann Arbor, Michigan $581M AUM 19.42% 1-Year Est. Return
MFS
McNamara Financial Services Marshfield, Massachusetts $580M AUM 17.89% 1-Year Est. Return
GFI
Global Frontier Investments Charleston, South Carolina $581M AUM 8.55% 1-Year Est. Return
PWM
Praetorian Wealth Management Carmel, California $580M AUM 19.43% 1-Year Est. Return
CA
COFG Advisors Oak Brook, Illinois $579M AUM

Prosight Management's Q3 2024 Portfolio in Review

As of Q3 2024, Prosight Management held 62 positions worth $406M, up 21% from $335M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Prosight Management deployed $62M of net new capital in Q3 2024, opening 16 new positions and adding to 17 existing holdings. Its largest new stake was McKesson: 35,822 shares worth $17.7M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Miscellaneous and Industrials.

On the sell side, the largest reduction was Lakefront Biotherapeutics American Depositary Shares, an estimated $8.74M trimmed.

  • Prosight Management's largest Q3 2024 buy was McKesson: 35,822 shares worth $17.7M.
  • Prosight Management added most to AbCellera Biologics in Q3 2024, an estimated $18.6M increase.
  • Prosight Management's biggest Q3 2024 reduction was Lakefront Biotherapeutics American Depositary Shares, cutting an estimated $8.74M.
  • Prosight Management fully exited Kelly Services Class A in Q3 2024, selling an estimated $10.5M.
  • Prosight Management's ten largest holdings make up 55% of its $406M portfolio in Q3 2024.
  • Prosight Management opened 16 new positions and closed 17 in Q3 2024.
  • Prosight Management's portfolio value rose 21% quarter-over-quarter to $406M.

Based on Prosight Management's 13F filing for Q3 2024, filed 14 Nov 2024.